Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eledon Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ELDN
Nasdaq
8731
https://eledon.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
- Mar 28th, 2024 8:01 pm
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
- Mar 25th, 2024 8:56 pm
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
- Mar 21st, 2024 2:31 pm
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 14th, 2024 12:01 am
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
- Jan 4th, 2024 9:40 pm
Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?
- Dec 25th, 2023 10:23 am
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
- Nov 29th, 2023 9:05 pm
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
- Nov 9th, 2023 9:01 pm
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
- Nov 8th, 2023 9:05 pm
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
- Nov 2nd, 2023 1:05 pm
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
- Oct 23rd, 2023 11:00 am
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
- Oct 13th, 2023 11:00 am
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
- Oct 2nd, 2023 11:00 am
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
- Sep 25th, 2023 11:00 am
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
- Sep 20th, 2023 8:05 pm
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
- Sep 6th, 2023 11:00 am
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
- Sep 5th, 2023 11:00 am
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
- Aug 16th, 2023 11:00 am
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
- Aug 10th, 2023 11:00 am
Amerigo Reports Q2-2023 Production Results and Provides MVC Operational Update
- Jul 12th, 2023 11:30 am
Scroll